Suzhou Glenco Pharmaceutical Technology

Suzhou Glenco Pharmaceutical Technology is a China-based biotechnology company focused on the discovery and development of novel small molecule therapeutics. Utilizing a robust platform centered on structure-based drug discovery (SBDD) and fragment-based drug discovery (FBDD), the company targets challenging protein-protein interactions (PPIs) that are often considered "undruggable." Their primary research efforts are directed toward oncology and immunology, with a specific emphasis on the apoptosis pathway, including targets like MCL-1 and BCL-2. Glenco integrates high-throughput screening, X-ray crystallography, and advanced medicinal chemistry to accelerate the identification of potent lead compounds. The company is headquartered in the Suzhou Industrial Park and maintains a strong focus on early-stage innovation and strategic research collaborations.